image credit- shutterstock
Jyong Biotech, a science-driven biotechnology company based in Taiwan committed to developing and commercialising innovative and differentiated new drugs (plant-derived) mainly specialising in the treatment of urinary system diseases, has entered into a non‑binding letter of intent (the LOI) with a South Korean pharmaceutical company to review and evaluate the potential in‑licensing and development of Jyong Biotech’s plant-derived new drug MCS-2for the Korean market.
The prospective partner is a recognised supplier to both general hospitals and clinics, and the LOI reflects mutual interest in assessing commercial and regulatory pathways for introducing MCS products in Korea.
Fu Feng Kuo, Chairwoman of Jyong Biotech, commented: “A selective co‑commercialisation approach with strategic partners will enable broader and faster patient access by combining its product development capabilities with partners’ commercial scale and local market knowledge. The company will work to advance LOI negotiation with these strategic partners and provide updates as material developments occur.”
As of present day, MCS-2 remains an investigational new drug candidate and has not been approved for commercial use in any jurisdiction. Jyong Biotech will comply with applicable regulatory disclosure obligations and provide timely, accurate, and complete updates on material developments.
